Pakistan Pharmaceuticals and Healthcare Report Q2 2012

  • ID: 2088108
  • February 2012
  • Region: Pakistan
  • 94 Pages
  • Business Monitor International
1 of 4


  • Abbott Laboratories
  • GlaxoSmithKline (GSK)
  • Novartis
  • Pfizer
  • Sanofi-Aventis
  • MORE

Business Monitor International's Pakistan Pharmaceuticals and Healthcare Report provides industry professionals and strategists, corporate analysts, pharmaceutical associations, government departments and regulatory bodies with independent forecasts and competitive intelligence on Pakistan's pharmaceuticals and healthcare industry.

BMI View: Despite the fact a significant number of multinationals are present in Pakistan, and the country's significant market potential, the leading international firms play a minimal role in the local pharmaceutical market – largely because of the unfavourable operating conditions. Problems include unreliable energy supply and security risks, as well as issues such as a poor drug approvals process and the weak enforcement of patent laws. The devolution of the Ministry of Health (MoH) and the disharmonisation of drug regulation will lead to further regulatory inefficiencies and more complex drug registration procedures for drugmakers, raising their operational costs and further suppressing drug company activity in Pakistan.

Headline Expenditure Projections:

Pharmaceuticals: PKR171.20bn (US$1.98bn) in 2011 to PRK190.28bn (US$2.07bn) READ MORE >

Note: Product cover images may vary from those shown
2 of 4


  • Abbott Laboratories
  • GlaxoSmithKline (GSK)
  • Novartis
  • Pfizer
  • Sanofi-Aventis
  • MORE

SWOT Analysis
Pakistan Pharmaceutical Industry SWOT
Pakistan Political SWOT
Pakistan Economic SWOT
Pakistan Business Environment SWOT

Pharmaceutical Risk/Reward Ratings
Table: Asia Pacific Pharmaceutical Risk/Reward Ratings, Q212

Pakistan – Market Summary

Regulatory Regime
Regulatory Developments
Intellectual Property Regime
Pricing Regime
Reimbursement Regime

Industry Trends And Developments
Non Communicable Diseases
Communicable Diseases
Public Health Developments
Healthcare System
Healthcare Insurance
Research And Development
Medical Devices

Industry Forecast Scenario
Pharmaceutical Market Forecast
Table: Pharmaceutical Sales Indicators 2008-2016
Key Growth Factors – Industry
Table: Healthcare Expenditure Indicators 2008-2016
Table: Healthcare Governmental Indicators 2008-2016
Table: Healthcare Private Indicators 2008-2016
Key Growth Factors – Macroeconomic
Pakistan – Economic Activity
Prescription Drug Market Forecast
Table: Prescription Drug Sales Indicators 2008-2016
Patented Drug Market Forecast
Table: Patented Drug Market Indicators 2008-2016
Generic Drug Market Forecast
Table: Generic Drug Sales Indicators 2008-2016
OTC Medicine Market Forecast
Table: OTC Medicine Sales Indicators 2008-2016
Medical Device Market Forecast
Table: Medical Devices Sales Indicators 2008-2016
Pharmaceutical Trade Forecast
Table: Exports and Imports Indicators 2008-2016
Other Healthcare Data Forecasts
Key Risks To BMI’s Forecast Scenario

Competitive Landscape
Pharmaceutical Sector
Table: 2008 Financial Snapshot Of Pakistani Drugmakers Listed On The Karachi Stock Exchange (US$mn)
Domestic Pharmaceutical Industry
Foreign Pharmaceutical Industry
Recent Pharmaceutical Sector Developments
Pharmaceutical Distribution Sector

Company Monitor
Local Manufacturers
Searle Pakistan
Hilton Pharma
Efroze Chemical Industries
Ferozsons Laboratories
Getz Pharma
Pacific Pharmaceuticals
Leading Multinational Manufacturers
GlaxoSmithKline (GSK)
Abbott Laboratories

Country Snapshot: Pakistan Demographic Data
Section 1: Population
Table: Demographic Indicators, 2005-2030
Table: Rural/Urban Breakdown, 2005-2030
Section 2: Education and Healthcare
Table: Education, 2002-2005
Table: Vital Statistics, 2005-2030
Table: Employment Indicators, 2001-2006
Section 3: Labour Market And Spending Power
Table: Consumer Expenditure, 2000-2012 (US$)
Table: Average Annual Manufacturing Wages, 2000-2012


BMI Methodology
How We Generate Our Pharmaceutical Industry Forecasts
Pharmaceuticals Business Environment Ratings
Risk/Reward Ratings Methodology
Ratings Overview
Table: Pharmaceutical Business Environment Indicators
Table: Weighting Of Components

Note: Product cover images may vary from those shown
3 of 4

- GlaxoSmithKline (GSK)
- Pfizer
- Abbott Laboratories
- Novartis
- Sanofi-Aventis

Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown


  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a single user license, allowing one specific user access to the product.


If you have a more general question about our products please try our



Our Clients

  • Pfizer Inc.
  • Grünenthal GmbH
  • GlaxoSmithKline PLC
  • Abbott Laboratories Ltd.
  • Roche Diagnostics Ltd.
  • Novo Nordisk A/S